Trimeric Tau is Toxic to Human Neuronal Cells at Low Nanomolar Concentrations

Overview

Journal Int J Cell Biol

Publisher Wiley

Specialty Cell Biology

Date 2013 Oct 26

PMID 24159335

Citations 52

Authors

Huilai Tian

Eliot Davidowitz

Patricia Lopez

Sharareh Emadi

James Moe

Michael Sierks

Affiliations

Soon will be listed here.

Abstract

In Alzheimer's disease (AD), tau aggregates into fibrils and higher order neurofibrillary tangles, a key histopathological feature of AD. However, soluble oligomeric tau species may play a more critical role in AD progression since these tau species correlate better with neuronal loss and cognitive dysfunction. Recent studies show that extracellular oligomeric tau can inhibit memory formation and synaptic function and also transmit pathology to neighboring neurons. However, the specific forms of oligomeric tau involved in toxicity are still unknown. Here, we used two splice variants of recombinant human tau and generated monomeric, dimeric, and trimeric fractions of each isoform. The composition of each fraction was verified chromatographically and also by atomic force microscopy. The toxicity of each fraction toward both human neuroblastoma cells and cholinergic-like neurons was assessed. Trimeric, but not monomeric or dimeric, tau oligomers of both splice variants were neurotoxic at low nanomolar concentrations. Further characterization of tau oligomer species with disease-specific modifications and morphologies is necessary to identify the best targets for the development of biomarker and therapeutic development for AD and related tauopathies.

Citing Articles

Mass spectrometry identifies tau C-terminal phosphorylation cluster during neuronal hyperexcitation.

Schneeweis A, Hillyer D, Lama T, Kim D, Palka C, Djemil S J Neurochem. 2024; 169(1):e16221.

PMID: 39308063 PMC: 11658181. DOI: 10.1111/jnc.16221.

"Prion-like" seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders.

Zampar S, Di Gregorio S, Grimmer G, Watts J, Ingelsson M Front Neurosci. 2024; 18:1436262.

PMID: 39161653 PMC: 11330897. DOI: 10.3389/fnins.2024.1436262.

Acute sleep deprivation in mice generates protein pathology consistent with neurodegenerative diseases.

Rowe R, Schulz P, He P, Mannino G, Opp M, Sierks M Front Neurosci. 2024; 18:1436966.

PMID: 39114483 PMC: 11303328. DOI: 10.3389/fnins.2024.1436966.

Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer's disease.

Jury-Garfe N, Redding-Ochoa J, You Y, Martinez P, Karahan H, Chimal-Juarez E Acta Neuropathol. 2024; 148(1):15.

PMID: 39102080 PMC: 11300572. DOI: 10.1007/s00401-024-02775-1.

Hairpin trimer transition state of amyloid fibril.

Sari L, Bali S, Joachimiak L, Lin M Nat Commun. 2024; 15(1):2756.

PMID: 38553453 PMC: 10980705. DOI: 10.1038/s41467-024-46446-x.

References

Ward S, Himmelstein D, Lancia J, Binder L . Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans. 2012; 40(4):667-71. PMC: 3704193. DOI: 10.1042/BST20120134. View

Haass C, Selkoe D . Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007; 8(2):101-12. DOI: 10.1038/nrm2101. View

Braak H, Braak E . Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997; 18(4):351-7. DOI: 10.1016/s0197-4580(97)00056-0. View

Belarbi K, Schindowski K, Burnouf S, Caillierez R, Grosjean M, Demeyer D . Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease. Curr Alzheimer Res. 2009; 6(2):152-7. PMC: 2859345. DOI: 10.2174/156720509787602843. View

Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs D, LaFerla F . Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006; 281(51):39413-23. DOI: 10.1074/jbc.M608485200. View

Pahlman S, Hoehner J, Nanberg E, Hedborg F, Fagerstrom S, Gestblom C . Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer. 1995; 31A(4):453-8. DOI: 10.1016/0959-8049(95)00033-f. View

Yoshiyama Y, Higuchi M, Zhang B, Huang S, Iwata N, Saido T . Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007; 53(3):337-51. DOI: 10.1016/j.neuron.2007.01.010. View

Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R . Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol. 2007; 171(3):976-92. PMC: 1959508. DOI: 10.2353/ajpath.2007.070345. View

Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker K, Barde Y . Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003; 86(3):582-90. DOI: 10.1046/j.1471-4159.2003.01879.x. View

10.

Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

11.

Witman G, Cleveland D, Weingarten M, Kirschner M . Tubulin requires tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A. 1976; 73(11):4070-4. PMC: 431332. DOI: 10.1073/pnas.73.11.4070. View

12.

Sierks M, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S . CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb). 2011; 3(12):1188-96. PMC: 3334303. DOI: 10.1039/c1ib00018g. View

13.

SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M . Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309(5733):476-81. PMC: 1574647. DOI: 10.1126/science.1113694. View

14.

Presgraves S, Ahmed T, Borwege S, Joyce J . Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox Res. 2004; 5(8):579-98. DOI: 10.1007/BF03033178. View

15.

Guillozet A, Weintraub S, Mash D, Marsel Mesulam M . Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003; 60(5):729-36. DOI: 10.1001/archneur.60.5.729. View

16.

Varvel N, Bhaskar K, Patil A, Pimplikar S, Herrup K, Lamb B . Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci. 2008; 28(43):10786-93. PMC: 2680286. DOI: 10.1523/JNEUROSCI.2441-08.2008. View

17.

Schliebs R, Arendt T . The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2010; 221(2):555-63. DOI: 10.1016/j.bbr.2010.11.058. View

18.

Zameer A, Schulz P, Wang M, Sierks M . Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry. 2006; 45(38):11532-9. DOI: 10.1021/bi060601o. View

19.

. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012; 8(2):131-68. DOI: 10.1016/j.jalz.2012.02.001. View

20.

Ferreira S, Vieira M, De Felice F . Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life. 2007; 59(4-5):332-45. DOI: 10.1080/15216540701283882. View